Vandetanib for the Treatment of Symptomatic or Progressive Medullary Thyroid Cancer in Patients with Unresectable Locally Advanced or Metastatic Disease: U.S. Food and Drug Administration Drug Approval Summary
Katherine A. Thornton(Memorial Sloan Kettering Cancer Center), Richard Pazdur(United States Food and Drug Administration), Brenda J. Gehrke(United States Food and Drug Administration), Wendy Wilson(Fred Hutch Cancer Center), Lisa Skarupa(National Institutes of Health), Robert T. Dorsam(United States Food and Drug Administration), V. Ellen Maher(United States Food and Drug Administration), Amna Ibrahim(Beni-Suef University), Anthony J. Murgo(National Cancer Institute), Anshu Marathe(Novartis (Switzerland)), Somesh Chattopadhyay(United States Food and Drug Administration), Robert Justice(United States Food and Drug Administration), Shenghui Tang(United States Food and Drug Administration), Christine Garnett(United States Food and Drug Administration), Debasis Ghosh(United States Food and Drug Administration), Suchitra Balakrishnan(United States Food and Drug Administration), Leigh Verbois(United States Food and Drug Administration), Pengfei Song(Henan University), Geoffrey Kim(United States Food and Drug Administration), Sarah Pope Miksinski(Center for Drug Evaluation and Research), Qi Liu(United States Food and Drug Administration), Hao Zhu(United States Food and Drug Administration), Young Jin Moon(United States Food and Drug Administration), Haripada Sarker(United States Food and Drug Administration), Brian Booth, John Duan
Cited by 149
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
|The Oncologist|2007|1.4k
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
|Clinical Cancer Research|2019|1.2k